Your browser doesn't support javascript.
loading
Is there delayed restenosis in patients with coronary artery disease treated with sirolimus-eluting stent?
Li, Jian-Jun; Xu, Bo; Yang, Yue-Jin; Chen, Ji-Lin; Qiao, Shu-Bing; Ma, Wei-Hua; Qin, Xue-Wen; Yao, Min; Liu, Hai-Bo; Wu, Yong-Jian; Yuan, Jin-Qing; Chen, Jue; You, Shi-Jie; Dai, Jun; Xia, Ran; Gao, Run-Lin.
Affiliation
  • Li JJ; Department of Cardiology, Fu Wai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China. lijnjn@yahoo.com.cn
Coron Artery Dis ; 18(4): 293-8, 2007 Jun.
Article in En | MEDLINE | ID: mdl-17496493
BACKGROUND: Although long-term follow-up after sirolimus-eluting stent implantation shows a sustained clinical benefit in several randomized and registered trials, little is known about the pattern of neointimal growth beyond the first 6 to 9 months. In this study, we therefore evaluated the possible delayed restenosis in patients with coronary artery disease treated with sirolimus-eluting stent. METHODS: A total of consecutive 333 patients with 453 lesions were enrolled in this study (among 782 consecutive patients with 1023 lesions). Lesions were subjected to follow-up by quantitative coronary angiography, and patients were divided into two groups according to the time of follow-up by quantitative coronary angiography: early group (< or =270 days, n=270 with 369 lesions) and late group (>270 days, n=63 with 84 lesions). Binary restenosis was defined as stenosis of more than 50% of the lumen diameter in the target lesion. RESULTS: Baseline clinical, demographic or angiographic characteristics were well balanced between the two groups. The in-stent restenosis rate was not significant between the early group and the late group (3.5 vs. 6.0%; P>0.05). The late loss and target lesion revascularization appeared higher in late group but there were no significant differences (0.15+/-0.38 mm vs. 0.24+/-0.44 mm; and 4.9 vs. 9.5%, P>0.05, respectively). Similarly, overall thrombosis rate was also same in both groups. In-segment restenosis was, however, higher in late group compared with that in early group (7.9 vs. 16.7%, P=0.013). CONCLUSION: In this unrestricted population, the beneficial effects of sirolimus-eluting stent implantation extend out more than 1 year in real world practice, that has been confirmed by the results of the large randomized clinical trials. The late in-segment restenosis could, however, be found, suggesting that a prolonged clinical and angiographic surveillance in this subset of patients seems to be warranted.
Subject(s)
Search on Google
Collection: 01-internacional Database: MEDLINE Main subject: Coronary Artery Disease / Stents / Sirolimus / Coronary Restenosis / Immunosuppressive Agents Type of study: Observational_studies Limits: Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Coron Artery Dis Journal subject: ANGIOLOGIA / CARDIOLOGIA Year: 2007 Document type: Article Country of publication: United kingdom
Search on Google
Collection: 01-internacional Database: MEDLINE Main subject: Coronary Artery Disease / Stents / Sirolimus / Coronary Restenosis / Immunosuppressive Agents Type of study: Observational_studies Limits: Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Coron Artery Dis Journal subject: ANGIOLOGIA / CARDIOLOGIA Year: 2007 Document type: Article Country of publication: United kingdom